Compound Radar

TransMedics Group, Inc. (TMDX) Stock Analysis

United States · Healthcare / Medical Devices

Price $88.27
Market cap $3.06B
Next earnings Oct 29, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

77
77/100 Elite Quality
  • Financial Health 75
  • Profitability 95
  • Business Quality 75
  • Balance Sheet 40
  • Cash Flow 80

Why this rating?

Health 77/100 — Elite Quality

Strongest Profitability 95/100
Softest Balance Sheet 40/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

TransMedics Group, Inc. (TMDX) is a Medical Devices company in the Healthcare sector. Compound Radar rates TransMedics Group, Inc. 77/100 (Elite Quality) due to high business quality, strong revenue growth, and elevated leverage.

Investment profile

  • Quality High
  • Growth Strong
  • Balance Sheet Stretched
  • Valuation Elevated

Financial highlights

Valuation

  • P/E 22.87
  • Forward P/E 38.29
  • PEG 0.77
  • EV/Revenue 5.26

Profitability

  • Revenue Growth 20.7%
  • Gross Margin 58.7%
  • Operating Margin 12.5%
  • Net Margin 22.7%
  • ROE 36.3%

Financial strength

  • Cash $472.68M
  • Debt $867.72M
  • Net Cash $-395.04M
  • Free Cash Flow $133.59M
  • Current Ratio 6.63

Similar companies

Peers in Medical Devices, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Devices →

FAQ

How Compound Radar scores and tracks TransMedics Group, Inc. (TMDX).

View Methodology & FAQ →